A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
Mitsukuni Suenaga,1 Nobuyuki Mizunuma,1 Satoshi Matsusaka,1 Eiji Shinozaki,1 Masato Ozaka,1 Mariko Ogura,1 Keisho Chin,1 Toshiharu Yamaguchi2 1Department of Gastroenterology, 2Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Res...
Main Authors: | Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-03-01
|
Series: | Drug Design, Development and Therapy |
Online Access: | http://www.dovepress.com/a-phase-iii-study-of-biweekly-capecitabine-and-irinotecan-plus-bevaciz-peer-reviewed-article-DDDT |
Similar Items
-
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
by: Suenaga M, et al.
Published: (2015-06-01) -
Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
by: Yeong Hak Bang, et al.
Published: (2021-03-01) -
Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal carcer
by: Jungić Saša, et al.
Published: (2017-01-01) -
Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
by: Satoru Iwasa, et al.
Published: (2023-04-01) -
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
by: Teschendorf Christian, et al.
Published: (2011-08-01)